Features | Partner Sites | Information | LinkXpress
Sign In
RG Advertising
KOREA E & EX
Schiller

Innovative Chair Allows Patients to Sit During Cancer Treatments

By HospiMedica International staff writers
Posted on 06 Dec 2012
A modified treatment chair used with cancer patients allows those who have problems lying down during procedures to sit upright, providing greater comfort.

The Procure intracranial chair was designed to address the difficulty some patients have when they need to lie flat for treatment. The chair also gives proton centers the option of using less expensive beam delivery systems rather than large gantry systems, as it was designed with multiple rotation points that complement the limited beam angles offered by the inclined or fixed beam systems. ProCure also developed the inclined beam technology, which can be used to treat approximately 80% of tumors that normally require the use of a gantry, but in a space about half the size, provided the chair can be attached to a robotic positioner. The intracranial chair was developed by Procure Treatment Centers (Procure, Bloomington, IN, USA).

“Some patients, especially those with head and neck tumors, have difficulty swallowing while lying on a standard treatment table,” said Eugen Hug, MD, medical director and chief medical officer at Procure. “Not only is this device helpful in greatly enhancing patient comfort but it improves patient flow by allowing us to use the inclined beam system for more people.”

“Our sole focus is providing exceptional patient care and we continue to do that by developing new innovations that place our patient’s comfort front and center,” said Niek Schreuder, senior vice president of medical physics and technology at ProCure. “Our engineers at the ProCure Training and Development Center strive to bring new and improved technology to cancer therapy, not only for our center but for all practices that are treating patients who could benefit.”

Proton therapy is an advanced form of radiation and an important alternative to standard X-ray radiation for many patients with cancer and for some noncancerous tumors. Proton therapy has been shown to be beneficial in the treatment of a broad range of tumor types including brain, central nervous system (CNS), gastrointestinal (GI), head and neck, lung, and prostate as well as sarcomas and many pediatric cancers. The precision of proton therapy makes it especially effective for treating children and adults with anatomically complex tumors such as base of skull and tumors along the spinal cord.

Related Links:
Procure Treatment Centers


Channels

Surgical Techniques

view channel

Raman Scattering Helps Evaluate Laser Ablation

Raman spectroscopy can be used to differentiate squamous cell carcinoma (SCC) from normal skin following treatment with high-powered lasers, according to a new study. Researchers at Florida Atlantic University (FAU; Boca Raton, USA) obtained 25 tissue samples from 11 patients undergoing Mohs micrographic surgery for... Read more

Women's Health

view channel

Nitrous Oxide for Labor Makes US Comeback

Long used for its anxiolytic properties during labor in European countries and Canada, nitrous oxide (N2O) use is resurging in the United States. While in countries such as Norway, New Zealand, Sweden, Australia, and England, usage rates of inhalational N2O during parturition reach 70%, it has only recently become an... Read more

Health IT

view channel
Image: Remote Intelligent Telehealth Assistant (RITA) (Photo courtesy of PR Newswire).

Telehealth Robot Launched to Increase Productivity of Doctors in Clinics and Hospitals

A robot uses high-definition monitors, high-speed components, and wireless communications, and serves as a telehealth media center to give doctors more flexibility in treating and assisting patients remotely.... Read more

Business

view channel

Pfizer to Buy Hospira to Bolster Hospital Products

Pfizer (New York, NY, USA) has entered into a definitive merger agreement with Hospira (Lake Forest, IL, USA), in a move designed to significantly enhance their global established pharmaceutical (GEP) business, for a total enterprise value of approximately USD 17 billion. The strategic complementary combination will... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.